Is viral status needed before vaccination?

This publication has 18 references indexed in Scilit:

• Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection
  JAMA, 2007
• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
  The Lancet, 2007
• Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials
  The Lancet, 2007
• Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases
  New England Journal of Medicine, 2007
• Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
  New England Journal of Medicine, 2007
• Prevalence of HPV Infection Among Females in the United States
  JAMA, 2007
• Human Papillomavirus Infection Among Sexually Active Young Women in the United States: Implications for Developing a Vaccination Strategy
  Sexually Transmitted Diseases, 2006
• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  The Lancet, 2006
• Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students
  American Journal of Epidemiology, 2003
• A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
  New England Journal of Medicine, 2002